Salubris Biotherapeutics (SalubrisBio), a subsidiary of Shenzhen Salubris Pharmaceuticals Co Ltd, is a biotechnology company that discovers and develops novel antibody and protein-based drugs to treat ...
Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Diastolic Heart Failure (HFpEF). According to GlobalData, Phase III drugs for Diastolic Heart Failure (HFpEF) ...
Heart failure with preserved ejection fraction (HFpEF) is a major health concern. Pathological stimuli and interactions between cardiac fibroblasts (CFs) and other cell types may lead to cardiac ...